Lawrence Berkeley National Laboratory

LBL Publications

Title

Discovery of novel geranylgeranyl reductases and characterization of their substrate promiscuity

Permalink <https://escholarship.org/uc/item/6ff8b198>

Journal Biotechnology for Biofuels and Bioproducts, 11(1)

ISSN

2731-3654

Authors

Meadows, Corey W Mingardon, Florence Garabedian, Brett M [et al.](https://escholarship.org/uc/item/6ff8b198#author)

Publication Date

2018-12-01

DOI 10.1186/s13068-018-1342-2

Peer reviewed

RESEARCH

Open Access

Discovery of novel geranylgeranyl reductases and characterization of their substrate promiscuity

Corey W. Meadows^{1,2†}, Florence Mingardon^{3†}, Brett M. Garabedian^{1,2}, Edward E. K. Baidoo^{1,2}, Veronica T. Benites^{1,2}, Andria V. Rodrigues^{1,2}, Raya Abourjeily³, Angelique Chanal³ and Taek Soon Lee^{1,2[*](http://orcid.org/0000-0002-0764-2626)}

Abstract

Background: Geranylgeranyl reductase (GGR) is a favin-containing redox enzyme that hydrogenates a variety of unactivated polyprenyl substrates, which are further processed mostly for lipid biosynthesis in archaea or chlorophyll biosynthesis in plants. To date, only a few GGR genes have been confrmed to reduce polyprenyl substrates in vitro or in vivo.

Results: In this work, we aimed to expand the confrmed GGR activity space by searching for novel genes that function under amenable conditions for microbial mesophilic growth in conventional hosts such as *Escherichia coli* or *Saccharomyces cerevisiae.* 31 putative GGRs were selected to test for potential reductase activity in vitro on farnesyl pyrophosphate, geranylgeranyl pyrophosphate, farnesol (FOH), and geranylgeraniol (GGOH). We report the discovery of several novel GGRs exhibiting signifcant activity toward various polyprenyl substrates under mild conditions (i.e., pH 7.4, *T*=37 °C), including the discovery of a novel bacterial GGR isolated from *Streptomyces coelicolor*. In addition, we uncover new mechanistic insights within several GGR variants, including GGR-mediated phosphatase activity toward polyprenyl pyrophosphates and the frst demonstration of completely hydrogenated GGOH and FOH substrates.

Conclusion: These collective results enhance the potential for metabolic engineers to manufacture a variety of isoprenoid-based biofuels, polymers, and chemical feedstocks in common microbial hosts such as *E. coli* or *S. cerevisiae.*

Keywords: Geranylgeranyl reductase, Redox enzymes, Isoprenoids, Hydrogenation, Terpene biosynthesis

Background

Manufacturing of terpenoid-based compounds has been studied extensively in synthetic biology. The two biosynthetic pathways for terpene monomer biosynthesis are the mevalonate and 1-deoxy-D-xylulose 5-phosphate pathways, where pyruvate is ultimately converted into either of the C_5 terpene building blocks, isopentenyl pyrophosphate or dimethylallyl pyrophosphate [\[1](#page-16-0), [2](#page-16-1)]. These monomer units are subsequently fused by various

BMC

Full list of author information is available at the end of the article

prenyl transferases to make geranyl pyrophosphate (GPP, C_{10}), farnesyl pyrophosphate (FPP, C_{15}), and geranylgeranyl pyrophosphate (GGPP, C_{20}) [[3\]](#page-16-2). The structural diversity of terpenes allows for a broad range of uses in

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License [\(http://creativecommons.org/licenses/by/4.0/\)](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/](http://creativecommons.org/publicdomain/zero/1.0/) [publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated.

^{*}Correspondence: tslee@lbl.gov

[†] Corey W. Meadows and Florence Mingardon contributed equally to this work

² Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

producing specially tailored natural products will require the use of novel chemistries and biosynthetic pathways. For example, isoprenoids have been considered as a promising precursor of alternative fuels, but reduction of isoprenoid double bonds is required to decrease the reactivity and sensitivity to oxidation and make them better fuels. Enzymatic alkene hydrogenation, however, is typically assisted by adjacent electron-withdrawing groups as observed in examples including old yellow enzyme, fatty acid enoyl reductases, and enone reductases [\[17](#page-16-9)–[20\]](#page-17-0).

Reduction of unactivated substrates like prenyl pyrophosphates typically involves oxidoreductases from the geranylgeranyl reductase (GGR) family. GGR generates fully saturated isoprenoid intermediates in archaeal membrane biosynthesis [[21,](#page-17-1) [22](#page-17-2)]. In archaea, GGR's native activity is believed to fully reduce all prenyl groups within the C_{20} isoprenoid chain of 2,3-di-O-geranylgeranylglyceryl phosphate (DGGGP) before carbon–carbon bond formation of reduced C_{20} isoprenoid chains form fully reduced C_{40} precursors needed for membrane synthesis [\[23,](#page-17-3) [24\]](#page-17-4). Moreover, in various organisms such as eukaryotes, bacteria, and archaea, GGRs also have been demonstrated to reduce a variety of prenylated substrates, including chlorophyll, tocopherol, dolichol, and menaquinone [\[25–](#page-17-5)[28\]](#page-17-6). However, very few GGRs have been confrmed as oxidoreductases, and most enzymes having prenyl reductase activity were derived from species that thrive under extremophilic conditions or utilize photosynthesis for energy transduction [[25](#page-17-5)[–32](#page-17-7)]. To date, only two crystal structures have been solved for GGRs from archaeal organisms. Reducing equivalents are thought to be derived from a NAD(P)H/ferredoxin reductase, in which electron transfer is conducted throughout the protein and modulated by a conserved active site cysteine within the cofactor binding domain, located directly behind the FAD isoalloxazine ring [\[31](#page-17-8)].

Biomanufacturing of reduced isoprenoid compounds requires a reductase activity under biologically relevant conditions required by bacterial and yeast strains (i.e., at 30–37 °C, at pH 7). In this study, we sought to increase the diversity space of GGRs by testing several dozen putative GGR sequences across a broad phylogeny, and we proceeded to test their associated substrate promiscuities under conditions ideal for microbial manufacturing (Scheme [1](#page-2-0)). Herein, we present signifcant insights on GGR activities that encompass newly confrmed GGR enzymes, novel substrate activities, and promiscuous catalysis.

Results and discussion

Selection and expression of potential GGR candidates The Interpro database (EMBL-EBI) predicts over 8000 proteins present within the GGR family (InterPro code: IPR011777), with many homologous genes containing sequence identities as low as 20–30%. After sequence alignment, a phylogeny tree includes 1787 sequences of predicted GGR from the InterPro database. A few GGRs within this database have been confrmed by other groups to reduce a wide variety of large prenylated substrates, including GGPP, DGGGP, geranylgeranylchlorophyll, menaquinone, and dolichol [[25–](#page-17-5)[32\]](#page-17-7). To investigate the in vitro prenyl reductase potential of other genes within the GGR family, we selected some with conserved sequence homologies to known GGRs and other more distant sequences. As observed in Fig. [1](#page-3-0), it was possible to observe some subgroups with conserved sequences (e.g., Mc, Sa, Pf or Hl, Hv1, Hs). Most of the sequences in the predicted GGR family, however, are very divergent. Our selection was then based on kingdom and diversity of species (e.g., archaea, algae, plant, cyanobacteria, and bacteria), on environmental diversity (e.g., temperatures, pH, aerobic or anaerobic), as well as particular

characteristics of some strains (e.g., *Corynebacterium terpenotabidum* or *Gordonia polyisoprenivorans* are actinomycetes capable of degrading squalene and rubber reciprocally). A few GGRs were also selected more randomly for their atypical sequences (Fig. [1\)](#page-3-0).

The 31 selected genes were codon optimized for *E. coli* expression and were all successfully transformed into *E. coli*. Initial expression attempts were not successful for many proteins using *E. coli* BL21 (DE3). However, by *E. coli* BL21 (DE3) strain harboring the commercially available pG-KJE8 plasmid overexpressing several *E. coli* chaperones, 24 of 31 strains overexpressed soluble proteins at the target masses for each protein, with each protein's presence in cell lysates confrmed by western blot containing the anti-His tag antibody (Fig. [2\)](#page-6-0). Out of them, only 12 proteins (Af, Cn, Ma, Mb, Mi, Mr2, Pf, Sa, Sc, Syn, Ta, and Tn) were obtained in sufficiently large quantities needed for activity assays after a standard purifcation and concentration process conducted at pH 7.4.

In vitro activity with isoprenoid alcohols

The 12 soluble proteins successfully isolated were tested for reductase activity on GGOH and FOH, and products obtained after enzymatic incubation were analyzed by GC–MS.

Out of the 12 purifed GGRs, fve were discovered to enzymatically reduce geranylgeraniol (GGOH). Neat GGOH substrate eluted at a retention time (RT) of 8.4 \pm 0.1 min (Fig. [3](#page-6-1)), with a directly proportional TIC response ranging from 0 to 200 μ M (Additional file [1](#page-15-0): Figure S1). Upon incubation with any of five putative GGRs isolated from *Archaeoglobus fulgidus* (AfGGR), *Methanocaldococcus infernus* (MiGGR), *Pyrolobus fumarii* (PfGGR), *Termococcus nautili* (TnGGR), or *Sulfolobus acidocaldarius* (SaGGR), several peaks eluting earlier than 8.4 min were observed (Fig. [3\)](#page-6-1). These peaks were assigned to structures of $H₂$ -GGOH $(RT=8.1\pm0.1 \text{ min})$, H₄-GGOH (RT = 7.9 \pm 0.1 min), and H₆-GGOH (RT = 7.7 \pm 0.1 min). Moreover, as protein concentration was increased, substrate consumption accelerated (Additional fle [1:](#page-15-0) Figure S2) with a concomitant increase in the formation of the various product peaks (data not showed), confrming enhanced isoprenoid reduction in the presence of higher concentration of enzymes. Out of all enzymes tested, SaGGR was the most active toward GGOH, with a specifc activity of at least 50 ± 10 nmol terpenoids reduced per milligram of enzyme per hour (Fig. [4](#page-8-0) and Table [2\)](#page-8-1). Typically, 70% of the initial GGOH would be recovered regardless of the varying amounts of reduced product formed. Hence, we assumed that all unrecovered substrate was unreduced, and the turnover numbers presented herein most likely represent a lower bound for reductase activity.

The H_2 -GGOH and H_4 -GGOH peaks have respective prevalent ion abundances at 261 and 263 *m*/*z*, which can be achieved by loss of a 31 Da $[M-CH₂OH]$ fragment during ionization and subsequent formation of a resonance-stabilized singly or doubly reduced geranylgeranyl fragment. Such fragments most likely originate from the prenyl units distal from the alcohol group being reduced frst, in accordance with previous mechanistic proposals performed using various substrates on a variety of GGRs [[29,](#page-17-9) [32](#page-17-7), [33\]](#page-17-10). Moreover, the H_6 -GGOH peak matches with a phytol peak from the NIST database with >90% probability, further reinforcing a mechanism of serial reduction of substrate beginning with the *δ*-prenyl group. Interestingly, several GGRs exhibit unknown side-products, with the most prevalent behavior observed between the H2-GGOH and H4-GGOH peaks in *Pyrolobus fumarii* GGR ($RT = 8.0$ min) (Fig. [3](#page-6-1)). This peak contains aberrant patterns for prenyl units within *m/z* window of 50–100, and we suggest these are H_4 -GGOH regioisomers in which one or both internal prenyl units are reduced first, which was suggested from the NIST database with >80% probability (Additional fle [1](#page-15-0): Figure S3).

Of most noteworthy interest is the product eluted at 7.5 ± 0.1 min RT from assays containing GGRs from *Sulfolobus acidocaldarius* (Fig. [3\)](#page-6-1). The mass spectra are matched against the 3,7,11,15-teramethylhexadecan-1-ol compound, a complete hydrogenation product of GGOH, in the NIST database with >88% probability. SaGGR, among others, has been demonstrated to reduce 3 out of 4 prenyl units of GGPP at best as observed in this work and others [[29](#page-17-9), [33](#page-17-10)]. Because a complete reduction is not observed in isoprenoid pyrophosphate substrates (Fig. [5\)](#page-9-0) but is observed in the isoprenoid alcohol (Fig. [3\)](#page-6-1), it seems that the absence of phosphate groups might facilitate enhanced difusion of the α-prenyl group to the favin reducing site in the alcohol substrates, leading to a fully reduced product. To our knowledge, this is the frst evidence of any nonnative isoprenoid substrate undergoing full reduction by any known or putative GGR enzyme.

Similarities in reducing activity were also prevalent using farnesol as a substrate. The unreduced FOH substrate eluted with a RT of 8.0 ± 0.1 min, with the putative singly (H₂-FOH) and doubly reduced (H₄-FOH) farnesol eluting at 7.6 ± 0.1 min and 7.4 ± 0.1 min, respectively (Fig. [6\)](#page-10-0). Farnesol ionization was also directly proportional to concentration ranging from 0 to 200 μ M (Additional file [1:](#page-15-0) Figure S1). The accompanying mass spectrum for H_2 -FOH reveals a similar ionization pattern to that observed in H_2 -GGOH via the prevalence of a strong 193 m/z peak. This parallels the H₂-GGOH peak pattern

| GGR name | Organism | Type | INTERPRO number | Molecular weight (kDa) |
|--------------------|---|---------------|------------------------|------------------------|
| AfGGR | Archaeoglobus fulgidus #1 | Archaea | >A0A075WA57 | 44 |
| Af2GGR | Archaeoglobus fulgidus #2 | Archaea | >A0A075WDX8 | 42 |
| AtGGR | Arabidopsis thaliana | Plant | $>$ Q9CA67 | 49 |
| CnGGR | Candidatus Nitrosopumilus | Archaea | >K0BBV2 | 47 |
| CtGGR | Corynebacterium terpenotabi- dum | Bacteria | >S4XGC5 | 49 |
| GpGGR | Gordonia polyisoprenivorans | Bacteria | $>$ H6N2C4 | 46 |
| HcGGR | Halorubrum californiensis | Archaea | >M0EA67 | 41 |
| HIGGR | Halostagnicola larsenii X | Archaea | >WOJLI3 | 52 |
| HsGGR | Haloterrigena salina | Archaea | >M0BU08 | 53 |
| Hv1GGR | Haloferax volcanii #1 | Archaea | >D4GXW9 | 53 |
| Hv2GGR | Haloferax volcanii #2 | Archaea | >D4H022 | 41 |
| Ma1GGR | Methanosarcina acetivorans #1 Archaea | | >Q8TQQ6 | 46 |
| Ma2GGR | Methanosarcina acetivorans #2 Archaea | | >Q8TLY0 | 47 |
| Ma3GGR | Methanosarcina acetivorans #3 Archaea | | >Q8TSV3 | 45 |
| MbGGR | Methanococcoides burtonii | Archaea | >Q12WF0 | 46 |
| McGGR | Metallosphaera cuprina | Archaea | >F4FYK4 | 53 |
| MiGGR | Methanocaldococcus infernus | Archaea | >D5VQY0 | 45 |
| MmGGR | Methanococcus maripaludis | Archaea | >Q6LXX0 | 45 |
| Mr1GGR | Methanobrevibacter ruminan- $ti \, \mu m \# 1$ | Archaea | >D3E3T0 | 45 |
| Mr2GGR | Methanobrevibacter ruminan- tium #2 | Archaea | >D3E430 | 51 |
| NgGGR | Nitrososphaera gargensis | Archaea | >KOIKB9 | 43 |
| PcfGGR | Pyrococcus furiosus | Archaea | >Q8U3L2 | 43 |
| PfGGR | Pyrolobus fumarii | Archaea | >GOEHJ8 | 53 |
| SaGGR | Sulfolobus acidocaldarius | Archaea | $>$ M1I414 | 52 |
| ScGGR | Streptomyces coelicolor #1 | Bacteria | >Q9K426 | 47 |
| SeGGR | Synechococcus elongatus #1 | Cyanobacteria | $>Q31QX9$ | 43 |
| SynGGR | Synechocystis species | Cyanobacteria | >L8ATV2 | 47 |
| TaGGR | Thermoplasma acidophilum #1 Archaea | | >Q9HKS9 | 45 |
| TnGGR | Thermococcus nautili | Archaea | >W8NRH6 | 46 |
| Tr1GGR | Thermocrinis ruber #1 | Bacteria | >W0DGJ3 | 41 |
| Tr _{2GGR} | Thermocrinis ruber #2 | Bacteria | >W0DID8 | 42 |

Table 1 Table of proteins tested for potential enzymatic isoprenoid reductase activity

The molecular weight of the enzymes includes the N-terminal His tag sequence

containing one less prenyl group $(m/z=70 \text{ Da})$. This suggests that the terminal isoprenoid unit is also reduced frst in farnesol, conserving the enzymatic reduction mechanism regardless of substrate. The H_4 -FOH peak at 7.4 min more closely resembles the H_6 -GGOH peak, with identical peak groupings near the 71, 81, and 123 *m/z* parent fragments.

Unlike GGOH, all GGRs appeared to have similar levels of FOH products under standard assay conditions, exhibiting an average specific activity of $7±2$ nmol terpenoid groups reduced mg^{-1} enzyme h^{-1} (Fig. [4](#page-8-0) and Table [1\)](#page-5-0). Notably, reduction patterns in TnGGR on FOH difer slightly from the other GGRs under standard assay conditions, as its major product is H_2 -FOH instead of

 H_4 H_4 -FOH (Fig. 4). No fully reduced farnesol peaks were observed under standard assay conditions nor at enzyme concentrations as high as $150 \mu M$ at pH 7.4. However, SaGGR generated a modest amount of H_6 -FOH when incubated under the enzyme's optimal conditions at 50 °C and pH 5.5 [[33\]](#page-17-10) (Additional fle [1:](#page-15-0) Figure S4).

Compared to GGOH, emergent side products are less prevalent in the farnesol TICs. Whereas multiple peaks were observed between the singly and doubly reduced GGOH (Fig. [3\)](#page-6-1), a single prevalent peak at 7.8 min elutes between FOH and H_2 -FOH, mainly observed when incubated in the presence of Pf and MiGGR (Fig. 6). The associated mass spectrum is tentatively assigned to a regioisomer of H_2 -FOH where the middle prenyl unit is

reduced first (Additional file [1](#page-15-0): Figure S5). The spectrum matches the NIST database for (*E*)-3,7,11-trimethyldodeca-2,10-dien-1-ol with a probability of 85% (Additional file [1:](#page-15-0) Figure S5). Many of the aberrant mass groupings between 50 and 100 m/z (Additional file [1:](#page-15-0) Figure S5) parallel those observed in the GGOH reaction incubated with PfGGR (Additional fle [1:](#page-15-0) Figure S3). However, the 7.8-min peak does not contain the m/z 193 ion. This ion could be formed by cyclization of a $[M-CH₂OH]$ fragment containing a reduced terminal prenyl group and is absent in products where the middle group is reduced frst due structural rigidity associated with the remnant $α-$ and γ-prenyl groups. This observation, coupled with the aberrant TIC product profle observed with GGOH, suggests a promiscuous mechanism in which PfGGR has been observed to reduce prenyl monomers out of order with respect to their polymeric structural order.

In vitro activity with isoprenoid pyrophosphates

The 12 soluble GGRs successfully purified were tested for reductase activity on FPP and GGPP, and products were detected by LC–MS–TOF. Both farnesyl pyrophosphate (FPP, $m/z = 381.123 \pm 0.001$ Da) and geranylgeranyl pyrophosphate (GGPP, *m/z*=449.183±0.002 Da) standards eluted with a retention time of 1.70 ± 0.05 min

(Fig. [5\)](#page-9-0); both substrates produced linear standard curves over a concentration range of 0–120 µM (Additional fle [1:](#page-15-0) Figure S6). When incubated with GGR under standard assay conditions, reduced isoprenoid products were observed to co-elute with fully oxidized substrate under isocratic LC conditions. Therefore, only normalized LC–MS–TOF spectra were utilized to distinguish the relative levels reduced and oxidized compounds that co-elute after incubating with GGRs isolated from various species (Additional fle [1:](#page-15-0) Table S1).

Interestingly, all proteins in this study discovered to enzymatically reduce prenyl pyrophosphates revealed co-eluting side products indicative of substrate or product hydrolysis of one phosphate moiety (Fig. [5](#page-9-0)). Increased abundances of farnesyl monophosphate (FP, $m/z = 301.177 \pm 0.001$ Da) or geranylgeranyl monophosphate (GGP, $m/z = 369.213 \pm 0.003$ Da) only emerged when incubated with enzyme; minimal hydrolysis was observed in GGPP or FPP standards and relative GGPP/ GGP and FPP/FP ratios remained constant as a function of time in negative controls ran without enzyme (Additional fle [1:](#page-15-0) Figure S7). Structural studies of SaGGR crystallized with GGPP revealed three distinct substrate binding modes with varying degrees of phosphorylation within each binding position [\[33](#page-17-10)]. Within the

(See fgure on next page.)

Fig. 3 (Top) normalized TIC profiles of five putative GGRs (Af, red; Pf, green; Mi, blue; Sa, magenta; Tn, orange; no enzyme, black) found to reduce GGOH (RT = 8.31 min) to H₂-GGOH (RT = 8.12 min), H₄-GGOH (RT = 7.85 min), H₆-GGOH (RT = 7.72 min), and H₈-GGOH (RT = 7.52 min) upon 1 h incubation under standard assay conditions. All peaks elute with a relative error of ± 0.05 min. (Bottom) the associated mass spectra for GGOH (blue), H₂-GGOH (green), H₄-GGOH (red), H₆-GGOH (orange), H₈-GGOH (gray) are shown with signature ions used for structural assignment of products

Table 2 Specifc activities of various enzymatic GGR reduction on geranylgeraniol and farnesol

| | GGOH^a | FOH^ª | |
|--------------|-------------------------|------------------------|--|
| Af GGR | 22(5) | 9(2) | |
| MiGGR | 10(2) | 8(2) | |
| PfGGR | 9(1) | 7(1) | |
| TnGGR | 20(5) | 5(1) | |
| SaGGR | 50(10) | 8(1) | |
| | | | |

 $^{\mathrm{a}}$ Units reported in nmol terpene units reduced mg $^{-1}$ enzyme h $^{-1}$

catalytically relevant binding mode, both phosphate moieties are resolved. In the other two binding modes, however, either one or zero phosphate group was structurally resolved. This was attributed to dephosphorylation during the crystallization process [[33\]](#page-17-10). Herein, we observed a time-dependent emergence of hydrolyzed monophosphate products via LC–MS–TOF; yet it still requires further characterization how the enzyme facilitates this phenomenon while conducting substrate reduction.

Reductase activity on FPP and GGPP varied from what was observed on alcohol substrates (Fig. [7\)](#page-11-0). Indeed, none of the GGRs tested could signifcantly reduce all vinyl groups within FPP or GGPP even when GGRs were incubated under the optimal condition for enzyme activity (at 50 °C and pH 5.5) (data not shown). Out of the fve GGRs found to reduce FOH, only PfGGR, TnGGR, and SaGGR could reduce FPP. On the other hand, three GGRs isolated from *Streptomyces coelicolor* (ScGGR), *Methanosarcina acetivorans* (MaGGR), and *Thermoplasma acidophilum* (TaGGR) were found to reduce GGPP along with the fve GGRs demonstrating reductase activity toward GGOH. Most GGRs that have been isolated thus far were from archaea; to our knowledge, ScGGR is the frst bacterial GGR demonstrated to reduce GGPP. Due

to unexpected hydrolysis of one phosphate moiety under standard assay conditions, specifc activities for reduction were not quantifed for any GGR. However, relative reductase activities can be gleaned by quantifying the proportion of reduced and unreduced compounds present within intact or hydrolyzed mass groupings (Fig. [7](#page-11-0)). For example, the relative ion intensities of each singly reduced product $(H_2$ -FPP or H_2 -FP) present is normalized to the sum of FPP, H_2 -FPP, H_4 -FPP, H_6 -FPP, FP, H_2 -FP, H_4 -FP, and H_6 -FP extracted ion intensities.

Interestingly, all GGRs revealed a larger proportion of reduced products present as hydrolyzed moieties than non-hydrolyzed moieties (Fig. [7](#page-11-0)). To discern a correlation between enzymatic phosphate hydrolysis and enzymatic reduction of prenyl monophosphates, we assayed PfGGR and SaGGR as a function of time, as these enzymes are representative of low and high amounts of monophosphate found after standard assay incubation, respectively (Additional fle [1:](#page-15-0) Figure S7). Indeed, substrate hydrolysis appears to react as a frst-order exponential process which occurs more quickly in SaGGR than for PfGGR (Additional fle [1](#page-15-0): Figure S8). Moreover, the relative abundances of reduced monophosphate products increase over time in both assays, indicating that most GGRs can still reduce FP or GGP as a substrate during substrate hydrolysis (Additional file [1](#page-15-0): Figure S9). Such an inference is reasonable considering many GGRs assayed enzymatically reduce terpenoid alcohols and pyrophosphates.

Promiscuous hydrolysis complicates any interpretations regarding which enzymes are most active toward a given substrate due to the inability to quantify the MS response of terpenoid phosphates. However, it can be inferred that all GGRs can reduce between 5 and 10 nmol prenyl groups of FPP or GGPP mg^{-1} enzyme h^{-1} . The turnover number would be modestly elevated for GGPP reduction, as all C_{20} species are extracted as some

partially reduced product within error after 1 h. Such turnover numbers are in line with other reports on GGRs with a variety of substrates [\[32,](#page-17-7) [33](#page-17-10)].

Structural insights and mechanistic implications

Several synthetic approaches are currently being explored to perform selective hydrogenation on a few substrates [\[34](#page-17-11)[–36](#page-17-12)]. Biological systems such as enoyl-CoA reductase and old yellow enzyme exhibit a similar oxidoreductase activity to GGR, yet beneft from active sites that enhance the electron-withdrawing nature of α,β-unsaturated carbonyl substrates [\[17–](#page-16-9)[20\]](#page-17-0). Patented ene-reductases utilizing old yellow enzyme as a scafold enhance reductase activity on a variety of substrates by evolving active sites complementary to a variety of electron withdrawing groups among a diverse variety of α,βunsaturated substrates [[37\]](#page-17-13). However, an evolved GGR active site designed for isoprenoid reduction would probably require signifcant divergence from these scafolds since they do not utilize electron-withdrawing activation for alkene reduction [[30\]](#page-17-14).

Of the eight proteins that were identifed as GGRs active toward terpenoid alcohols and/or terpenoid pyrophosphates, fve (Sa-, Pf-, Af-, Mi-, and TnG-GRs) were isolated from archaeal organisms that

optimally thrive under hyperthermophilic conditions (i.e., *T*≥80 °C). SaGGR, TaGGR, and AfGGR have been identifed to reduce various large intermediates (i.e., larger than 20 carbons) associated with archaeal lipid biosynthesis, with GGPP or GGOH serving as the smallest substrates known to undergo prenyl reduction [[27](#page-17-15), [29,](#page-17-9) [32\]](#page-17-7). In this study, we have signifcantly expanded the known GGR substrate activity profles, demonstrating multiple prenyl group reduction in GGOH and FOH within all fve hyperthermophilic GGRs.

In addition to the fve GGRs active on alcohols, TaGGR, MaGGR, and ScGGR also sufficiently reduced GGPP or GGP (Figs. [5](#page-9-0) and [7](#page-11-0)). However, only PfGGR, SaGGR, and TnGGR were found to reduce the smaller FPP or FP substrates. Because the relative amount of H_2 -, H_4 -, and H_6 -GGOH increase in relative abundances within the monophosphate mass groupings relative to the pyrophosphate mass groupings, it can be inferred that prenyl monophosphates are also substrates reduced by several GGRs (Additional file [1](#page-15-0): Figure S9). This seems suitable given the ability of several GGRs to reduce prenyl alcohols.

A structural alignment of all eight active GGRs reveals very little commonalities among all protein sequences with known crystal structures: SaGGR and TaGGR,

FOH (RT = 8.00 min) to H₂-FOH (RT = 7.58 min) or H₄-FOH (RT = 7.40 min) upon 1 h incubation under standard assay conditions. All peaks elute with a retention time error of \pm 0.05 min. (Bottom) the associated mass spectra for each peak are shown with signature molecular ions for structural assignment of products

with PfGGR ca. 46% identical to SaGGR and MaGGR, MiGGR, and AfGGR ca. 40–46% identical to TaGGR (Fig. [8](#page-12-0)). SaGGR and TaGGR contain three domains: an FAD binding domain, a catalytic domain, and a C-terminal domain [[29,](#page-17-9) [30\]](#page-17-14). While sequence identities remain low among all demonstrably active GGRs, certain key structural motifs remain conserved within their predicted FAD binding domains and catalytic domains. Of the two known crystal structures of active GGRs, both contain an active site cysteine (Cys47 in SaGGR; Cys45 in TaGGR) thought to serve as a critical redox modulator within the active site during reduction. All GGRs shown to reduce either isoprenoid alcohols or pyrophosphates contain this critical cysteine within their cofactor binding domains, suggestive of a conserved electron transfer mechanism. In addition, all sequences predicted catalytic domains contain the YXWXFP (SaGGR residues 215– 220) and GGG motifs (SaGGR residues 298–300) believed to modulate substrate interactions and assist in substrate difusion through the reduction center.

Protein structures of aligned sequences were predicted using either SaGGR or TaGGR as a template. While there is a fair amount of expected structural divergence among the structures' surfaces, a comparison of the active sites reveals a fair degree of similarity in topology (Fig. [9](#page-13-0)). However, some of the structural motifs strictly conserved among all archaeal GGRs exhibit signifcant divergence within ScGGR, the only known GGR to be isolated from a bacterial organism. While all archaeal GGRs studied in this work possess a YXWXFPX $_{7.8}$ GXG motif, the terminal glycine is mutated to isoleucine in ScGGR. Even more interestingly, the GGG motif has signifcantly diverged to REG in ScGGR. In several GGRs from photosynthetic organisms with demonstrated capability to reduce prenylated chlorophyll, *Rhodobacter sphaeroides*, *Synechocystis* sp. *PCC 6803*, and *Arabidopsis thaliana*, this motif was found to be GEG [[26,](#page-17-16) [38](#page-17-17), [39](#page-17-18)]. It seems that non-archaeal GGRs utilize preferentially charged residues within this critical catalytic region to either enhance polar interactions on prenylated substrates containing polar groups or to introduce critical hydrogen-bonding interactions that help maintain the integrity of the substrate tunnel during reduction (Fig. [9](#page-13-0)).

Mechanistic interpretations from other groups propose that the prenyl group closest to the pyrophosphate moiety (α-prenyl group) remains oxidized in GGPP and FPP. This observation additionally applies to their monophosphate counterparts in this work, FP and GGP. All enzymes tested to date seem to conserve this characteristic of avoiding reduction at the α -position on phosphate intermediates, aligning with current paradigms that auxiliary prenyl reductases are responsible for reducing this group in archaea and eukaryotes [[40\]](#page-17-19).

To our knowledge, full isoprenoid reduction by GGR has only been observed with its natural C_{40} isoprenoid substrate DGGGP. In this work, we observed full reduction for the first time on smaller (i.e., C_{20} or C_{15}) isoprenoid alcohol substrates, namely GGOH and FOH with SaGGR (Figs. [3](#page-6-1), [4,](#page-8-0) [6](#page-10-0), Additional fle [1:](#page-15-0) Figure S4). Interestingly, the absence of phosphate groups appears to assist in full substrate reduction. Analysis of the catalytically relevant binding mode of GGPP in SaGGR reveals that binding site residues His55 and Asn90 could provide hydrogen bonding interactions with phosphate moieties that could prevent the α -prenyl group from being reduced [[33\]](#page-17-10). Alcohol substrates may not interact as strongly with these residues, facilitating a degree of full reduction unobserved in pyrophosphate substrates. Why some enzymes reduce isoprenoid alcohol and pyrophosphate substrates, while others only reduce isoprenoid pyrophosphates requires further structural characterization.

Conclusions

In this study, we have signifcantly expanded the possible activities among proteins demonstrated to enzymatically reduce prenyl pyrophosphates or prenyl alcohols. We have demonstrated (1) the discovery of four novel protein sequences (PfGGR, MiGGR, ScGGR, and TnGGR) that have confrmed GGR activity in vitro in addition to expanded observed activities among previously characterized GGRs; (2) that several GGRs can reduce C_{15} terpenoid substrates, substrates smaller than reported substrates for GGR activity; (3) the complete reduction of double bonds on any C_{20} or C_{15} isoprenoid using SaGGR; (4) reductase activity on terpenoid monophosphates formed from hydrolysis of pyrophosphate substrates under reducing conditions in vitro; (5) the quantifcation of reductase specifc activity on terpenoid alcohols; and (6) the confrmed isoprenoid reductase activity of the second known non-archaeal enzyme, as observed in the GGR isolated from *Streptomyces coelicolor*.

This demonstration of protein expression and reductase activity at neutral pH and low temperature highlights their potential suitability for integration into *S. cerevisiae* or *E. coli*. Moreover, the confirmation of reduction on C_{15} isoprenoids instantly expands the metabolic engineering potential for organisms producing sterol and squalenederived isoprenoids. There are still unresolved issues to address for a direct application of these newly discovered GGRs to manufacture reduced isoprenoids. For example, more engineering will be needed on these enzymes to avoid enzymatic hydrolysis of isoprenoid pyrophosphates

and to improve their activities especially at mesophilic condition. Nonetheless, this study demonstrated signifcant substrate promiscuity among these GGRs and could potentially open new pathways for isoprenoid-based polymers, chemicals, or biofuels by allowing for upstream reduction of various intermediates within the heavily utilized MEV or DXP terpene biosynthesis pathways.

Methods

All chemicals and reagent were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise indicated. (*E*,*E*)-farnesol was purchased from Alfa Aesar (Haverhill, MA) and glycerol from VWR (Westchester, PA). Solvents for high performance liquid chromatography (HPLC) were purchased from HoneyWell Burdick and Jackson (Morristown, NJ) and were of HPLC grade or higher. Ammonium carbonate (30-33% NH₃ basis) was purchased from Fluka Analytical Sigma-Aldrich (St. Louis, MO). Restriction enzymes and polymerases were purchased from New England Biolabs (Ipswich, MA).

Sequence analysis and GGR homology

Multiple sequence alignments for potential GGR hits were generated using MUSCLE v. 3.8.31 and visualized using Geneious 7.0.6 [[41,](#page-17-20) [42](#page-17-21)]. Sequences were curated manually, and phylogeny trees were computed using the maximum likelihood tree within the RAxML Software package, v. 8.1.24 under the LG plus gamma

model of evolution (PROTGAMMALG in the RAxML model section) $[43]$ $[43]$. The MRE-based bootstrapping criterion was automatically determined for phylogeny tree construction. Annotation of the tree was performed in Itol [\[44](#page-17-23)]. After verifcation of GGR activity, the active enzymes underwent a second multiple sequence alignment and modeled for their predicted protein structures via SWISS-MODEL-PDB using either SaGGR or TaGGR as templates [[45\]](#page-17-24). Active site geometries and local structures for all proteins were visualized using Chimera [[46](#page-17-25)].

Plasmid synthesis and transformation

The gene encoding SaGGR was amplified by PCR from the pSKB3-SaGGR plasmid using the forward (5′-GAT ATACATATGAAGGAACTTAAATATGACGTTCTG -3′) and reverse (5′-GTCGACGGAGCTCGAACTTAA ACTTTTGTTAAACTCTGTTAGAAC-3′) primers synthesized by Integrated DNA Technologies $[33]$ $[33]$ $[33]$. The PCR fragment was digested at the *Nde*I and *Sac*I restriction sites and cloned into the pET-24a vector using the rapid DNA ligation kit (Roche). All other putative GGR genes were synthesized by GeneWiz (NJ, USA) and similarly cloned into the pET-24a vector at the same restriction sites. All gene constructs are available through the JBEI registry at <http://public-registry.jbei.org>(Table [1](#page-5-0) and Additional fle [1](#page-15-0): Table S2).

Ten nanogram of each plasmid was transformed by heat shock at 42 °C for 1 min into chemically competent *E. coli* BL21 cells harboring the pG-KJE8 plasmid encoding DnaK, DnaJ, GrpE, GroES, and GroEL protein chaperones (Takara Bio Inc., Shiga, Japan). Transformed cells were recovered in 1 mL of Lysogeny Broth (LB) medium (VWR) and incubated for 1 h at 37 °C with shaking at 200 rpm. Following recovery, cells were plated on LB Agar containing 50 mg/L of kanamycin (VWR) and 30 mg/L of chloramphenicol (VWR), and incubated overnight at 37 °C. Select colonies were grown overnight in LB medium containing 50 mg/L of kanamycin and 30 mg/L of chloramphenicol and stored in 20% glycerol (VWR) at -80 °C for future use.

Cell culture, protein expression, and protein purifcation

Overnight seed cultures of 1 mL each were inoculated into 400 mL of Terrifc Broth (TB) medium supplemented with 50 mg/L kanamycin and 30 mg/L chloramphenicol and incubated at 37 °C and 200 rpm. At an OD₆₀₀ of 0.2– 0.3, chaperone overexpression was induced with 5 ng/ mL tetracycline (VWR) and 2.5 mM arabinose (Sigma-Aldrich). After the OD_{600} reached ≥ 1.0 , GGR expression was induced with 0.1 mM IPTG (VWR) and incubated at 18 °C overnight. Cells were pelleted at 6000×*g* for 10 min and immediately lysed using 20 mM phosphate bufer, pH 8.0 containing 1 mg/mL lysozyme, 20 mM imidazole, 200 mM NaCl, and 0.1 mM PMSF protease inhibitor (Sigma-Aldrich). After sonication for 10 min, the remaining cell debris was pelleted at 15,000×*g* for 45 min.

Protein expression was tested for each construct using SDS-PAGE and Western blot. For SDS-PAGE analysis, protein samples were normalized for concentration using absorbance at 280 nm. Lysates were diluted with $2\times$ SDS loading dye buffer (Life Technologies, CA, USA) containing 10 mM DTT (Sigma-Aldrich) and incubated at 98 $°C$ for 20 min. 10 µL of denatured lysate samples was loaded onto an 8–16% Tris–Glycine–SDS gradient gel (Bio-Rad), and separated using a voltage of 180 V in Tris–Glycine–SDS running bufer (Bio-Rad). Gels were either directly stained using GelCode Blue Safe Protein Stain (Thermo-Fisher) or transferred to a nitrocellulose membrane using the trans-Blot Turbo system (Life Technologies, CA, USA) for analysis by Western blot. Membranes were washed in TBS bufer (50 mM Tris, 150 mM NaCl, pH 7.4) and blocked overnight at 4 °C with 25 mL of 3% BSA in TBS-Tween20 (Sigma-Aldrich). The monoclonal mouse anti-His primary antibody (Sigma-Aldrich) was diluted 5000-fold, and an alkaline phosphataseconjugated goat anti-mouse secondary antibody was diluted 10,000-fold in TBS-Tween20 containing 1% BSA. Membranes were incubated with antibodies for 1 h each at room temperature and washed three times in TBS-Tween20 after each antibody incubation. The membrane was then incubated in 10 mL of SigmaFast BCIP/NBT

Alkaline Phosphatase detection solution (Sigma-Aldrich) for 10 min.

To further characterize those putative GGRs that showed signifcant protein expression, the cells harboring them were cultured in 400 mL of TB-Kan/Cm media and lysed as previously described. Their respective crude lysates were loaded directly onto a 1 mL HisTrap Fast-Flow column (GE Healthcare), washed with ten column volumes of 20 mM phosphate bufer containing 20 mM imidazole and 200 mM NaCl at pH 7.4, then eluted with the same buffer containing 240 mM imidazole. For enzyme kinetics, purifed enzymes were bufer exchanged using 20 mM phosphate buffer at pH 7.4 and concentrated to 200–800 μM using 30 KDa molecular weight cutoff spin concentrators (EMD Millipore). Purified proteins were stored in 10% (v:v) glycerol and snap frozen in liquid nitrogen. Protein purity and sizes were verifed by SDS-PAGE and protein concentrations were quantifed by absorbance at 280 nm using each protein's calculated extinction coefficient via the ExPASY ProtParam tool.

In vitro enzyme kinetics assays

Validation of enzymatic substrate reduction was determined by incubating all assays in triplicate for each respective substrate and putative GGR for 1 h at 37 °C. All assays were performed at pH 7.4 in 100 mM sodium phosphate buffer containing $30-150 \mu M$ enzyme, $200 \mu M$ FAD (Sigma-Aldrich), and 65 mM sodium dithionite (Sigma-Aldrich). Standard assays for alcohol reduction were incubated with 100 μ M enzyme and 500 μ M (*E*,*E*)-farnesol (Alfa-Aesar) or (*E*,*E*,*E*)-geranylgeraniol (Sigma-Aldrich); pyrophosphate assays were performed at 100 µM FPP or GGPP (Sigma-Aldrich). Alcohol-based assays were quenched by liquid extraction using a 3:1 (v:v) LC-grade ethyl acetate solution containing 100 µM dodecanol as a GC internal standard (Sigma-Aldrich). The organic layer was extracted and stored at −20 °C until analysis by GC– MS. Pyrophosphate assays were similarly quenched using LC-grade *n*-butanol (Sigma-Aldrich) 1:1 (v:v) and centrifuged at 15,000 \times *g* for 2 min. The *n*-butanol layer was dried for 45 min at ambient temperature using a Labconco speedvac, reconstituted in 25 μ L of a 62:38 (v:v) acetonitrile/50 mM ammonium carbonate solution, and stored at −20 °C until further analysis by LC–MS–TOF [[33\]](#page-17-10). Characterization of enzymatic hydrolysis of isoprenoid pyrophosphate substrates by SaGGR and PfGGR was performed by quenching the enzyme reactions at 0, 2, 5, 10, 20, 40, and 60 min of incubation.

Analysis of alcohol reduction by GC–MS

Product identifcation and quantifcation of farnesol and hydrofarnesol derivatives were modifed from previous

detection methods [\[47\]](#page-17-26). All GC–MS analyses were determined using an Agilent 6890 gas chromatography instrument coupled to an Agilent 5973 mass selective detector. 1 µL of extracted samples was injected in splitless mode onto an Agilent CycloSil-B column, with helium used as a carrier gas fowing at 1.0 mL/min. Following injection, the oven was held at 50 °C for 30 s, then increased to 175 °C at 35 °C/min. Farnesol and hydrofarnesols were resolved by increasing the temperature 4 °C/min up to 200 °C, then increased to 300 °C at a rate of 35 °C/min where it was held for 1.5 min. Geranylgeraniol and its hydrogenated derivatives were analyzed using the same injection method. After injection, the oven was held at 50 °C for 30 s, then increased to 235 °C at 35 °C/min. Hydrogeranylgeraniols were separated by increasing the oven temperature 4 °C/min to 250 °C, then ramped to 300 °C at a rate of 35 °C/min where it was held for 1.5 min.

The EI–MS detection was initiated after a solvent delay of 5.0 min. Detection and classifcation of hydrofarnesols were performed in scan mode at 9.8 scans/s ranging from 50 to 250 *m/z* in positive ion mode. For geranylgeraniol, the same scan parameters were implemented except for the mass range, which was expanded to 50–300 *m/z* in positive ion mode. The electron multiplier voltage was set to a gain factor of 1, with the MS ion source and quadrupole set to 230 °C and 150 °C, respectively.

Total ion chromatograms (TIC) were integrated using Agilent Technologies Masshunter software, version 6. Product formation was determined from the TIC area for C_{15} or C_{20} alcohol products eluting at each respective retention time. Absolute product concentrations were determined from standard curves $(0-200 \mu M)$ of either farnesol or geranylgeraniol assuming the TIC area of each reduced product ionizes with an equivalent efficiency to that of the unreduced substrate (Additional file [1:](#page-15-0) Figure S1). Subsequently, enzyme turnover numbers for isoprenoid reduction were calculated as the total number of nanomoles of prenyl units reduced per milligram of enzyme in 1 h.

Analysis of pyrophosphate reduction by LC–MS–TOF

The separation of FPP, GGPP, and their reduced forms was conducted on a ZIC-pHILIC column (150 mm length, 2.1 mm internal diameter, and $5 \mu m$ particle size, Merck) using an Agilent Technologies 1200 Series Rapid Resolution high-performance liquid chromatography (HPLC) system. Solvents for HPLC were purchased from HoneyWell and were of HPLC grade or higher. The mobile phases used for this analysis were (A) 50 mM ammonium carbonate (Fluka, 30–33% NH₃ basis) in water and (B) acetonitrile. Analytes were eluted isocratically with a mobile phase composition of 62% B at a flow rate of 0.2 mL/min. The total run time of the method was 6.5 min. The temperature of the sample tray was maintained at 6 $°C$ using an Agilent FC/ALS Thermostat. The column compartment was set to 40 °C. A sample injection volume of 2 μ L was used throughout [\[33\]](#page-17-10).

The HPLC system was coupled to an Agilent Technologies 6210 time-of-fight mass spectrometer (LC–TOF– MS) by a 1/3 post-column split. Contact between both instrument set-ups was established using a LAN card to trigger the MS into operation upon the initiation of a run cycle from the MassHunter workstation (Agilent Technologies). Electrospray ionization (ESI) was conducted in the negative ion mode and a capillary voltage of -3500 V was utilized. MS experiments were carried out in full scan mode, at 0.86 spectra/second for the detection of [M−H][–] ions. The instrument was tuned for a range of 50–1700 *m/z*. Prior to LC–TOF–MS analysis, the TOF– MS was calibrated via an ESI-L low concentration tuning mix (Agilent Technologies).

Data acquisition and processing were performed by the Agilent Technologies MassHunter software package. Product formation was determined using extracted ion chromatogram abundances (± 0.02) Da) for each molecule's [M−H]− mass (Additional fle [1:](#page-15-0) Table S1). Substrate and product hydrolysis of SaGGR and PfGGR was characterized as a function of time by measuring the relative ratios of prenyl pyrophosphates (FPP/GGPP and reduced products) and monophosphates (FP/GGP and reduced products) at quenched fractions collected at 0, 2, 5, 10, 20, 40, and 60 min. Relative reductase reactivity among GGRs was determined by measuring the fractional abundance of singly, doubly, or triply reduced products to the total ion abundance present for intact and hydrolyzed moieties [[33\]](#page-17-10). Integrated areas for hydrolyzed monophosphate products were assumed to have the same ionization intensities as their pyrophosphate counterparts, as determined by their standard curves measured from 0 to 120 μ M (Additional file [1:](#page-15-0) Figure S6).

Additional fle

Additional file 1: Figure S1. TIC for neat GGOH (RT = 8.4 min, top) and FOH (RT = 8.0 min, middle) substrates. The standard curve for quantifying farnesol (circles) and geranylgeraniol (squares) by GC–MS (bottom) exhibited a linear response for both substrates between 0 and 200 μ M. **Figure S2.** Verification of accelerated substrate reduction as a function of enzyme concentration for GGOH (left) and FOH (right) for the Af (circles), Mi (squares), Tn (flled triangles), Sa (flled upside down triangles), and Pf (unflled triangles) GGR enzymes. Specifc activities are quoted in Table [1.](#page-5-0) **Figure S3.** Comparison of mass spectra between a side product containing one internal prenyl group reduced within $H₄$ -GGOH with an 8.0 min retention time (Top, black) and the assigned product with the terminal prenyl group reduced in H₄-GGOH eluting at 7.7 min (Bottom, green). **Figure S4.** (Top) normalized TIC of farnesol activity assay incubated for 2 h with SaGGR at 50 °C, pH 5.5 showing a modest abundance of fully

reduced farnesol (RT = 7.0 \pm 0.1 min). For reference, FOH and H₄-FOH elute at retention times of 7.9 and 7.3 min, respectively. H₂-FOH (RT=7.5 min) was not observed in any quantifable abundance. All substrate and cofactor concentrations were held constant. **Figure S5.** Comparison of mass spectra between the middle prenyl group reduced within the putative H₂-FOH side product eluting at 7.8 min retention time (Top, black) and the assigned product with the terminal prenyl group reduced in H₂-FOH eluting at 7.6 min (Bottom, green). **Figure S6.** Standard curve for quantifying FPP (circles) and GGPP (squares) by LC–MS–TOF. **Figure S7.** MS-TOF Spectrum of 100 µM FPP and GGPP standards (Top). (Bottom) relative abundances of GGPP and GGP (left) or FPP and FP (middle) after incubation under standard assay conditions; negative controls containing all assay components without enzyme (right) rule out the possibility of spontaneous hydrolysis of substrate, as the ratio of pyrophosphate (dark gray) to monophosphate (light gray) products remain constant as a function of time. Reduced products within each mass grouping are included in the total abundance. **Figure S8.** Demonstration that frst-order substrate hydrolysis catalyzed by either SaGGR (squares) or PfGGR (triangles) in either FPP (left) or GGPP (right). The no enzyme control (circles) contained all assay components except enzyme. **Figure S9.** Timecourse comparison of the standard assay for SaGGR (top row) and PfGGR (bottom row) on either GGPP or FPP substrates. Pyrophosphate abundances are shown in the left column and monophosphate abundances are shown in the right column under each substrate. Products are expressed as having zero reductions (blue), one reduction (green), two reductions (red), or three reductions (orange). **Table S1.** Masses used to analyze various products formed from GGR standard assays incubated with prenyl pyrophosphates. ^aMasses reported are for the deprotonated [M−H]⁻ parent ion in negative mode detection. **Table S2.** Table of plasmids used in the present study. The strains harboring individual plasmid are available at the public registry of the Joint BioEnergy Institute [\(https://](https://public-registry.jbei.org/) [public-registry.jbei.org/\)](https://public-registry.jbei.org/) under the ID's listed in the righthand column.

Abbreviations

GPP: geranyl pyrophosphate; FPP: farnesyl pyrophosphate; GGPP: geranylgeranyl pyrophosphate; FOH: farnesol; GGOH: geranylgeraniol; GGR: geranylgeranyl reductase; LC–MS: liquid chromatography–mass spectrometry; TOF: time of fight; GC–MS: gas chromatography–mass spectrometry; TIC: total ion chromatogram.

Authors' contributions

CWM, FM, AC and TSL conceived the project. CWM, FM, BMG, TSL drafted the manuscript, reviewed and edited the fnal manuscript. CWM, FM, BMG, EEKB, VTB, AVR, and RA performed the experiments and analyzed data. All authors read and approved the fnal manuscript.

Author details

¹ Joint BioEnergy Institute, 5885 Hollis Street, 4th floor, Emeryville, CA 94608, USA. ² Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.³ Total Raffinage Chimie, 2 Pl. Jean Millier, 92400 Courbevoie, France.

Acknowledgements

We thank Dr. Jay Keasling for support during the early stage of this project and for his editing assistance.

Competing interests

TSL has fnancial interest in Maple Bio.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate Not applicable.

Funding

This work was part of the DOE Joint BioEnergy Institute [\(https://www.jbei.org](https://www.jbei.org)) supported by the US Department of Energy, Office of Science, Office of Biological and Environmental Research, through contract DE-AC02-05CH11231 between Lawrence Berkeley National Laboratory and the US Department of Energy. This work, funded by Total, was performed as part of a collaborative program between JBEI and Total.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

Received: 11 September 2018 Accepted: 15 December 2018

References

- 1. Rohmer M. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat Prod Rep. 1999;16(5):565–74.
- 2. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30.
- 3. Liang PH, Ko TP, Wang AHJ. Structure, mechanism and function of prenyltransferases. Eur J Biochem. 2002;269(14):3339–54.
- 4. Meadows CW, Kang A, Lee TS. Metabolic engineering for advanced biofuels production and recent advances toward commercialization. Biotechnol J. 2018;13(1):14.
- 5. de Carvalho C, da Fonseca MMR. Biotransformation of terpenes. Biotechnol Adv. 2006;24(2):134–42.
- 6. Guimaraes AG, Serafni MR, Quintans LJ. Terpenes and derivatives as a new perspective for pain treatment: a patent review. Expert Opin Ther Patents. 2014;24(3):243-65.
- 7. Winnacker M, Rieger B. Recent progress in sustainable polymers obtained from cyclic terpenes: synthesis, properties, and application potential. Chemsuschem. 2015;8(15):2455–71.
- 8. Ajikumar PK, Tyo K, Carlsen S, Mucha O, Phon TH, Stephanopoulos G. Terpenoids: opportunities for biosynthesis of natural product drugs using engineered microorganisms. Mol Pharm. 2008;5(2):167–90.
- 9. Dickschat JS. Bacterial terpene cyclases. Nat Prod Rep. 2016;33(1):87–110. 10. Pazouki L, Niinemets U. Multi-substrate terpene synthases: their occur-
- rence and physiological signifcance. Front Plant Sci. 2016;7:16. 11. Bohlmann J, Meyer-Gauen G, Croteau R. Plant terpenoid synthases: molecular biology and phylogenetic analysis. Proc Natl Acad Sci USA. 1998;95(8):4126–33.
- 12. Ajikumar PK, Xiao WH, Tyo KEJ, Wang Y, Simeon F, Leonard E, Mucha O, Phon TH, Pfeifer B, Stephanopoulos G. Isoprenoid pathway optimization for taxol precursor overproduction in *Escherichia coli*. Science. 2010;330(6000):70–4.
- 13. Lubben M, Morand K. Novel prenylated hemes as cofactors of cytochrome oxidases. Archaea have modifed hemes A and O. J Biol Chem. 1994;269(34):21473–9.
- 14. Martin VJJ, Pitera DJ, Withers ST, Newman JD, Keasling JD. Engineering a mevalonate pathway in *Escherichia coli* for production of terpenoids. Nat Biotechnol. 2003;21(7):796–802.
- 15. Surmacz L, Swiezewska E. Polyisoprenoids—secondary metabolites or physiologically important superlipids? Biochem Biophys Res Commun. 2011;407(4):627–32.
- 16. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241–69.
- 17. De Wildeman SMA, Sonke T, Schoemaker HE, May O. Biocatalytic reductions: from lab curiosity to "frst choice". Accounts Chem Res. 2007;40(12):1260–6.
- 18. Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res. 2003;42(4):289–317.
- 19. Stuermer R, Hauer B, Hall M, Faber K. Asymmetric bioreduction of activated C=C bonds using enoate reductases from the old yellow enzyme family. Curr Opin Chem Biol. 2007;11(2):203–13.
- 20. Toogood HS, Gardiner JM, Scrutton NS. Biocatalytic reductions and chemical versatility of the old yellow enzyme family of favoprotein oxidoreductases. ChemCatChem. 2010;2(8):892–914.
- 21. Jain S, Caforio A, Driessen AJM. Biosynthesis of archaeal membrane ether lipids. Front Microbiol. 2014;5:16.
- 22. Koga Y, Morii H. Biosynthesis of ether-type polar lipids in archaea and evolutionary considerations. Microbiol Mol Biol Rev. 2007;71(1):97–120.
- 23. Murakami M, Shibuya K, Nakayama T, Nishino T, Yoshimura T, Hemmi H. Geranylgeranyl reductase involved in the biosynthesis of archaeal membrane lipids in the hyperthermophilic archaeon *Archaeoglobus fulgidus*. FEBS J. 2007;274(3):805–14.
- 24. Sato S, Murakami M, Yoshimura T, Hemmi H. Specifc partial reduction of geranylgeranyl diphosphate by an enzyme from the thermoacidophilic archaeon *Sulfolobus acidocaldarius* yields a reactive prenyl donor, not a dead-end product. J Bacteriol. 2008;190(11):3923–9.
- 25. Mizoguchi T, Isaji M, Yamano N, Harada J, Fujii R, Tamiaki H. Molecular structures and functions of chlorophylls-a esterifed with geranylgeranyl, dihydrogeranylgeranyl, and tetrahydrogeranylgeranyl groups at the 17-propionate residue in a diatom, *Chaetoceros calcitrans*. Biochemistry. 2017;56(28):3682–8.
- 26. Addlesee HA, Hunter CN. Physical mapping and functional assignment of the geranylgeranyl-bacteriochlorophyll reductase gene, bchP, of *Rhodobacter sphaeroides*. J Bacteriol. 1999;181(23):7248–55.
- 27. Hemmi H, Takahashi Y, Shibuya K, Nakayama T, Nishino T. Menaquinonespecifc prenyl reductase from the hyperthermophilic archaeon *Archaeoglobus fulgidus*. J Bacteriol. 2005;187(6):1937–44.
- 28. Naparstek S, Guan ZQ, Eichler J. A predicted geranylgeranyl reductase reduces the omega-position isoprene of dolichol phosphate in the halophilic archaeon, *Haloferax volcanii*. Biochim Biophys Acta Mol Cell Biol Lipids. 2012;1821(6):923–33.
- 29. Sasaki D, Fujihashi M, Iwata Y, Murakami M, Yoshimura T, Hemmi H, Miki K. Structure and mutation analysis of archaeal geranylgeranyl reductase. J Mol Biol. 2011;409(4):543–57.
- 30. Xu QP, Eguchi T, Mathews II, Rife CL, Chiu HJ, Farr CL, Feuerhelm J, Jaroszewski L, Klock HE, Knuth MW, et al. Insights into substrate specifcity of geranylgeranyl reductases revealed by the structure of digeranylgeranylglycerophospholipid reductase, an essential enzyme in the biosynthesis of archaeal membrane lipids. J Mol Biol. 2010;404(3):403–17.
- 31. Isobe K, Ogawa T, Hirose K, Yokoi T, Yoshimura T, Hemmi H. Geranylgeranyl reductase and ferredoxin from *Methanosarcina acetivorans* are required for the synthesis of fully reduced archaeal membrane lipid in *Escherichia coli* cells. J Bacteriol. 2014;196(2):417–23.
- 32. Ogawa T, Isobe K, Mori T, Asakawa S, Yoshimura T, Hemmi H. A novel geranylgeranyl reductase from the methanogenic archaeon *Methanosarcina acetivorans* displays unique regiospecifcity. FEBS J. 2014;281(14):3165–76.
- 33. Kung Y, McAndrew RP, Xie XK, Liu CC, Pereira JH, Adams PD, Keasling JD. Constructing tailored isoprenoid products by structure-guided modifcation of geranylgeranyl reductase. Structure. 2014;22(7):1028–36.
- 34. Blaser HU, Malan C, Pugin B, Spindler F, Steiner H, Studer M. Selective hydrogenation for fne chemicals: recent trends and new developments. Adv Synth Catal. 2003;345(1–2):103–51.
- 35. Stephan DW. Frustrated Lewis pairs: from concept to catalysis. Accounts Chem Res. 2015;48(2):306–16.
- 36. Noyori R, Hashiguchi S. Asymmetric transfer hydrogenation catalyzed by chiral ruthenium complexes. Accounts Chem Res. 1997;30(2):97–102.
- 37. Maurer S, Hauer B, Bonnekessel M, Faber K, STÜCKLER C: a process for the enzymatic reduction of enoates. Google Patents; 2011.
- 38. Shpilyov AV, Zinchenko VV, Shestakov SV, Grimm B, Lokstein H. Inactivation of the geranylgeranyl reductase (ChlP) gene in the cyanobacterium *Synechocystis* sp. PCC 6803. Biochim Biophys Acta-Bioenerg. 2005;1706(3):195–203.
- 39. Keller Y, Bouvier F, D'Harlingue A, Camara B. Metabolic compartmentation of plastid prenyllipid biosynthesis—evidence for the involvement of a multifunctional geranylgeranyl reductase. Eur J Biochem. 1998;251(1–2):413–7.
- 40. Eichler J, Guan ZQ. Lipid sugar carriers at the extremes: the phosphodolichols Archaea use in N-glycosylation. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(6):589–99.
- 41. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32(5):1792–7.
- 42. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, et al. Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012;28(12):1647–9.
- 43. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and postanalysis of large phylogenies. Bioinformatics. 2014;30(9):1312–3.
- 44. Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 2016;44(W1):W242–5.
- 45. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Cassarino TG, Bertoni M, Bordoli L, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014;42(W1):W252–8.
- 46. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12.
- 47. Rodriguez S, Kirby J, Denby CM, Keasling JD. Production and quantifcation of sesquiterpenes in *Saccharomyces cerevisiae*, including extraction, detection and quantifcation of terpene products and key related metabolites. Nat Protoc. 2014;9(8):1980–96.

Ready to submit your research? Choose BMC and benefit from:

- **•** fast, convenient online submission
- **•** thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- **•** gold Open Access which fosters wider collaboration and increased citations
- **•** maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

